Press release
Remicade Biosimilar Market Size, Trends, Analysis And Forecast 2024-2033
Remicade Biosimilar Market Size
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp
According to The Business Research Company's, The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, healthcare cost pressures.
The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report
Market Drivers and Trends:
The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Autoimmune diseases are disorders in which the immune system mistakenly attacks and damages the body's tissues and organs. Remicade biosimilars are used in treating autoimmune diseases by providing an effective therapeutic option to manage the symptoms and reduce inflammation associated with these. For instance, in October 2021, according to the reports shared by the City University of London, a UK-based public university, in the UK, 7%, or 4 million people, were suffering from autoimmune diseases by 2021, and over 80 autoimmune illnesses were identified with increasing prevalence annually by 3-9%. Furthermore, in July 2021, according to the Cleveland Clinic, a US-based, non-profit academic medical center, autoimmune diseases affected 1 in 15 people, with 1.4 million individuals having Crohn's disease or ulcerative colitis, while 1 million people had lupus in 2021. Therefore, the rise in the incidence of autoimmune diseases is driving the growth of the Remicade biosimilar market.
Product innovation is a key trend gaining popularity in the Remicade biosimilar market. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market. For instance, in January 2023, Amgen Inc, a US-based biotechnology company, launched Amjevita, a biosimilar version of AbbVie's Humira, in the US, designed to be as safe and effective as the original drug. Amjevita is the first biosimilar to Humira and is expected to compete with Humira for market share. It is a biological drug used to treat various autoimmune diseases, including rheumatoid arthritis and Crohn's disease. It is one of the most expensive drugs in the world, generating billions of dollars in sales for AbbVie each year. Amjevita is expected to cost significantly less. In addition to saving money, Amjevita can also offer patients more treatment options.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
AbbVie Inc., Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Organon & Co., Merck And Co. Inc., Janssen Biotech Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvogen Inc, Synthon International Holding B.V., Coherus Biosciences Inc, Cardinal Health Inc, Genentech Inc., Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A
Remicade Biosimilar Market 2024 Key Insights:
• The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%.
• Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth
• Innovative Biosimilar Launches Shape Remicade Market Landscape
• Europe was the largest region in the remicade biosimilar market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=11952&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
"""Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Remicade Biosimilar Market Size, Trends, Analysis And Forecast 2024-2033 here
News-ID: 3763485 • Views: …
More Releases from The Business research company
Competitive Analysis: Leading Companies and New Entrants in the Wire Arc Additiv …
The wire arc additive manufacturing cell market is rapidly gaining traction as industries increasingly embrace advanced metal 3D printing technologies. With significant investments and technological breakthroughs, this sector is set to experience remarkable growth, transforming manufacturing processes across multiple fields. Let's explore the market's size, influential players, key trends, and segmentation to understand its future trajectory.
Projected Expansion of the Wire Arc Additive Manufacturing Cell Market
The wire arc additive manufacturing cell…
Future Perspectives: Key Trends Shaping the Viscosupplementation Treatment for A …
The viscosupplementation treatment for arthritis market is on the verge of significant expansion, driven by advances in medical technology and a growing demand for effective arthritis therapies. With increasing awareness around early intervention and new treatment options, this sector is poised for rapid development over the coming years. Let's explore the market size, key players, emerging trends, and segment-wise forecasts that define this growing industry.
Projected Market Growth and Size of…
Segmentation, Major Trends, and Competitive Overview of the Viral Vector Develop …
The viral vector development service market is set to experience substantial growth in the coming years, driven by technological progress and increasing demand from various sectors. As gene therapies and advanced treatments gain prominence, the need for efficient viral vector production and development is becoming more critical. Let's explore the market size projections, key players, emerging trends, and the segment structure shaping this industry's future.
Projected Expansion and Market Size of…
Competitive Landscape: Leading Companies and New Entrants in the Transient Elast …
The transient elastography market is poised for substantial expansion as advancements in healthcare diagnostics continue to evolve. Increasing emphasis on non-invasive techniques and early disease detection is driving widespread adoption, setting the stage for strong market growth in the coming years. Let's explore the current market valuation, leading players, emerging innovations, and key segments shaping this industry.
Projected Market Value and Growth of the Transient Elastography Market
The transient elastography market is…
More Releases for Remicade
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
Affordable Innovation: 2024 Global Market Report on Remicade Biosimilars
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Remicade Biosimilar Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $9.1 billion In 2028 At…
Remicade Biosimilar Market Size & Growth Analysis Report, 2021-2027
Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Remicade Biosimilar Market at: https://www.orionmarketreports.com/remicade-biosimilar-2-market/48410/#ert_pane1-1
Segment by Type
• 100mg/10ml
• 500mg/50ml
Segment by Application
• Blood Disorders
• Oncology Diseases
By Company
• Synthon Pharmaceuticals
• LG Life Sciences
• Novartis (Sandoz)
• Celltrion
• Biocon
• Hospira
• Merck Serono (Merck Group)
• Biogen idec Inc
A full report of Global Remicade Biosimilar Market is available at: https://www.orionmarketreports.com/remicade-biosimilar-2-market/48410/
Scope of the Report
The research…
Biosimilar of Remicade Market Is Thriving Worldwide
In a recent S&R Research publish Global Biosimilar of Remicade Market Insights, Forecast to 2025, analysts provide an in-depth analysis of the global market for Biosimilar of Remicade. By analyzing its historical and forecast data, the analysis analyzes the different aspects of the market. Some are part of the coverage and are the core and emerging players being profiled Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), Celltrion, Biocon, Hospira, Merck…
Remicade (Infliximab) Biosimilar Clinical Trial Insight
“Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The…
Good Growth Opportunities in Global Remicade Biosimilar Market Till 2026
About the drug and drug class:
Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. Biosimilars are drugs licensed by U.S. FDA and European Medicine Agency (EMA) and reflect no clinical and meaningful differences from the reference products in terms of safety, purity, efficacy and effectiveness. These biosimilar drugs can only be approved for the…
